NL
LCTX icon

NWAM LLC’s Lineage Cell Therapeutics LCTX Stock Holding History

NWAM LLC’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,131
Closed -$98.8K – 656
2025
Q4 		$98.8K Buy
62,131
+27,131
+78% +$47K 0.01% 604
2025
Q3 		$57.4K Buy
35,000
+20,000
+133% +$23.7K ﹤0.01% 633
2025
Q2 		$15.3K Buy
+15,000
New +$8.9K ﹤0.01% 614

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NWAM LLC's LCTX Position: Q1 2026 in Review

NWAM LLC sold out of Lineage Cell Therapeutics (LCTX) in Q1 2026, closing a stake of 62,131 shares — an estimated $98.8K sold.

NWAM LLC first reported a position in LCTX in Q2 2025 and held it in 3 quarters. The position peaked at $98.8K in Q4 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • NWAM LLC reported no remaining Lineage Cell Therapeutics position as of Q1 2026 after selling out during the quarter.
  • NWAM LLC sold 62,131 Lineage Cell Therapeutics shares in Q1 2026, an estimated $98.8K.
  • NWAM LLC first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 3 quarters.
  • NWAM LLC's Lineage Cell Therapeutics position peaked at $98.8K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on NWAM LLC's 13F filing for Q1 2026, filed 4 May 2026.